Catalent Expands European Clinical Packaging Capabilities
Catalent Pharma Solutions has tannounced several expanded capabilities within its European Clinical Supply Services network. The expansions have been implemented in response to increased customer demand for specialty clinical packaging, where the proportion of highly potent or temperature-sensitive investigational medical products continues to increase.
At its Schorndorf, Germany, facility, Catalent tripled its frozen storage (-18 °C) capacity and has added a second automated Inova packaging line for pre-filled syringes, with capabilities including plunger-rod insertion, application of single panel labels, finger flanges, and safety device mounting. At its controlled substances facility in Deeside, UK, the company has expanded its clinical storage capacity with the addition of a third vault, bringing the combined controlled substance storage capacity to over 14,000 cubic feet. The Bathgate, UK facility’s cold storage capabilities have been updated to include a cryogenic storage service, suitable for stem cells, regenerative therapies and other clinical materials.
And finally, at Catalent’s primary packaging facility, in Bolton, UK, the company has installed two new energy-efficient chiller units that increase output capacity by more than 10%.
“As with our recent investments in our US capabilities, we are committed to offering comprehensive clinical supply solutions throughout our European network,” commented Gerry Hepburn, Chief Operating Officer, Vice President and General Manager of Catalent’s Clinical Supply Services business. “A key part of that commitment is ensuring that our facilities are well aligned with the current, emerging and future needs of our customers, as evidenced by our recent investments in Europe and the harmonization of key systems across all Catalent sites.”
The 60,000 sq ft Schorndorf facility offers primary and secondary packaging for oral dose solids and pre-filled syringes; cold, frozen and controlled drug clinical storage; and EU-GMP audit, importation, release and consulting services. The 125,000 sq ft Deeside facility provides comprehensive primary and secondary packaging services, with extensive capabilities in the cold storage of temperature-sensitive and controlled drug substances handling. The 141,000 sq ft Bathgate facility provides primary and secondary packaging services and returns and destruction management. The 61,000 sq ft Bolton facility offers state-of-the-art clinical supply services and is capable of supporting a range of primary and secondary packaging projects, from early stage clinical studies to specialty commercial packaging needs, including cold storage or highly-potent drugs handling. All four sites provide end-to-end clinical supply solutions that also include clinical supply management and comparator sourcing.
Related News
-
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Pharma Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain. -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement. -
News BIOSECURE Act continues to loom over Chinese pharma manufacturers
With the US BIOSECURE Act on its way to passing into legislation, Chinese companies are facing declining revenues within the first half of 2024 as US pharmaceutical and healthcare companies pull their businesses from the country. -
News Ophthalmologic drug product Eylea faces biosimilar threats after FDA approvals
Regeneron Pharmaceutical’s blockbuster ophthalmology drug Eylea is facing biosimilar competition as the US FDA approves Biocon’s Yesafili and Samsung Bioepis/Biogen’s Opuviz. -
News ONO Pharmaceutical expands oncology portfolio with acquisition of Deciphera
ONO Pharmaceutical, out of Japan, is in the process of acquiring cancer-therapy maker Deciphera Pharmaceuticals for US$2.4 billion. -
News First offers for pharma from Medicare drug price negotiations
Ten high-cost drugs from various pharma manufacturers are in pricing negotiations in a first-ever for the US Medicare program. President Biden’s administration stated they have responded to the first round of offers. -
News Eli Lilly’s Zepbound makes leaps and bounds in weight-loss drug market
In the last week, Eli Lilly has announced their partnership with Amazon.com’s pharmacy unit to deliver prescriptions of Zepbound. Zepbound has also surpassed Novo Nordisk’s Wegovy for the number of prescriptions for the week of March 8.&nbs...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance